Logo image of IMV.CA

IMV Inc (IMV.CA) Stock Fundamental Analysis

TSX:IMV - Toronto Stock Exchange - CA44974L3011 - Common Stock - Currency: CAD

1.12  -0.02 (-1.75%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to IMV. IMV was compared to 25 industry peers in the Biotechnology industry. IMV may be in some trouble as it scores bad on both profitability and health. IMV is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IMV has reported negative net income.
IMV had a negative operating cash flow in the past year.
IMV had negative earnings in each of the past 5 years.
In the past 5 years IMV always reported negative operating cash flow.
IMV.CA Yearly Net Income VS EBIT VS OCF VS FCFIMV.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M

1.2 Ratios

The profitability ratios for IMV are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IMV.CA Yearly ROA, ROE, ROICIMV.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 -5K -10K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IMV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMV.CA Yearly Profit, Operating, Gross MarginsIMV.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 -5K -10K -15K -20K

More info and screens

2

2. Health

2.1 Basic Checks

IMV does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IMV has more shares outstanding
The debt/assets ratio for IMV is higher compared to a year ago.
IMV.CA Yearly Shares OutstandingIMV.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M
IMV.CA Yearly Total Debt VS Total AssetsIMV.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

2.2 Solvency

IMV has an Altman-Z score of -12.67. This is a bad value and indicates that IMV is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -12.67, IMV is not doing good in the industry: 69.70% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -12.67
ROIC/WACCN/A
WACC6.74%
IMV.CA Yearly LT Debt VS Equity VS FCFIMV.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M

2.3 Liquidity

IMV has a Current Ratio of 2.93. This indicates that IMV is financially healthy and has no problem in meeting its short term obligations.
IMV has a Current ratio (2.93) which is in line with its industry peers.
A Quick Ratio of 2.93 indicates that IMV has no problem at all paying its short term obligations.
IMV's Quick ratio of 2.93 is in line compared to the rest of the industry. IMV outperforms 51.52% of its industry peers.
Industry RankSector Rank
Current Ratio 2.93
Quick Ratio 2.93
IMV.CA Yearly Current Assets VS Current LiabilitesIMV.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 4.44% over the past year.
IMV shows a strong growth in Revenue. In the last year, the Revenue has grown by 37.21%.
IMV shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.12% yearly.
EPS 1Y (TTM)4.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.29%
Revenue 1Y (TTM)37.21%
Revenue growth 3Y-8.54%
Revenue growth 5Y14.12%
Sales Q2Q%337.14%

3.2 Future

Based on estimates for the next years, IMV will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.36% on average per year.
The Revenue is expected to grow by 162.00% on average over the next years. This is a very strong growth
EPS Next Y20.34%
EPS Next 2Y22.41%
EPS Next 3Y17.34%
EPS Next 5Y15.36%
Revenue Next Year-80.66%
Revenue Next 2Y59.28%
Revenue Next 3Y71.75%
Revenue Next 5Y162%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IMV.CA Yearly Revenue VS EstimatesIMV.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M
IMV.CA Yearly EPS VS EstimatesIMV.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IMV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IMV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMV.CA Price Earnings VS Forward Price EarningsIMV.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMV.CA Per share dataIMV.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

A more expensive valuation may be justified as IMV's earnings are expected to grow with 17.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.41%
EPS Next 3Y17.34%

More info and screens

0

5. Dividend

5.1 Amount

IMV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMV Inc

TSX:IMV (4/28/2023, 7:00:00 PM)

1.12

-0.02 (-1.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners13.52%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap13.12M
Analysts80
Price Target28.69 (2461.61%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.77%
Min EPS beat(2)18.66%
Max EPS beat(2)24.89%
EPS beat(4)4
Avg EPS beat(4)17.9%
Min EPS beat(4)11.99%
Max EPS beat(4)24.89%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)362.62%
Min Revenue beat(2)302.87%
Max Revenue beat(2)422.36%
Revenue beat(4)3
Avg Revenue beat(4)202.15%
Min Revenue beat(4)-14.65%
Max Revenue beat(4)422.36%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-7.8%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.5%
EPS NY rev (1m)-12.6%
EPS NY rev (3m)-782.93%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-50%
Revenue NY rev (1m)-84.75%
Revenue NY rev (3m)-88.34%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 27.46
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-6.19
EYN/A
EPS(NY)-4.93
Fwd EYN/A
FCF(TTM)-3.97
FCFYN/A
OCF(TTM)-3.85
OCFYN/A
SpS0.04
BVpS-0.76
TBVpS-0.76
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 107.19%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.93
Quick Ratio 2.93
Altman-Z -12.67
F-Score2
WACC6.74%
ROIC/WACCN/A
Cap/Depr(3y)151.06%
Cap/Depr(5y)243.84%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.29%
EPS Next Y20.34%
EPS Next 2Y22.41%
EPS Next 3Y17.34%
EPS Next 5Y15.36%
Revenue 1Y (TTM)37.21%
Revenue growth 3Y-8.54%
Revenue growth 5Y14.12%
Sales Q2Q%337.14%
Revenue Next Year-80.66%
Revenue Next 2Y59.28%
Revenue Next 3Y71.75%
Revenue Next 5Y162%
EBIT growth 1Y-8.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-7.84%
EBIT Next 3Y-3.45%
EBIT Next 5Y16.26%
FCF growth 1Y-3.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4.22%
OCF growth 3YN/A
OCF growth 5YN/A